[
  {
    "ts": null,
    "headline": "A Look at Johnson & Johnson’s Valuation Following Back-to-Back FDA Approvals for Oncology and Neuropsychiatry Therapies",
    "summary": "Johnson & Johnson (JNJ) just secured back-to-back FDA approvals for two therapies, representing a meaningful expansion in both its oncology and neuropsychiatry portfolios. These developments could open up additional opportunities for long-term growth. See our latest analysis for Johnson & Johnson. These approvals have come amid a stretch of strong momentum for Johnson & Johnson, with the stock delivering a robust 9.05% share price gain over the last quarter and an impressive 25.45% total...",
    "url": "https://finnhub.io/api/news?id=47d2c148f643063b7ff9e354c3562742d521bb9ab27c8cfbec12bc9079c42280",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762885159,
      "headline": "A Look at Johnson & Johnson’s Valuation Following Back-to-Back FDA Approvals for Oncology and Neuropsychiatry Therapies",
      "id": 137449891,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) just secured back-to-back FDA approvals for two therapies, representing a meaningful expansion in both its oncology and neuropsychiatry portfolios. These developments could open up additional opportunities for long-term growth. See our latest analysis for Johnson & Johnson. These approvals have come amid a stretch of strong momentum for Johnson & Johnson, with the stock delivering a robust 9.05% share price gain over the last quarter and an impressive 25.45% total...",
      "url": "https://finnhub.io/api/news?id=47d2c148f643063b7ff9e354c3562742d521bb9ab27c8cfbec12bc9079c42280"
    }
  },
  {
    "ts": null,
    "headline": "Medtronic: Possible Earnings Beat Incoming But Still Overvalued",
    "summary": "Medtronic plc offers reliable dividends and steady cash flow, but limited growth prospects make MDT stock a cautious hold. Click for my MDT earnings preview.",
    "url": "https://finnhub.io/api/news?id=728b6f2f10d052e542a15011fdef72ee2f6ff39e49f7cc4e571f06743480c9ec",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762877094,
      "headline": "Medtronic: Possible Earnings Beat Incoming But Still Overvalued",
      "id": 137450342,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1481143570/image_1481143570.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Medtronic plc offers reliable dividends and steady cash flow, but limited growth prospects make MDT stock a cautious hold. Click for my MDT earnings preview.",
      "url": "https://finnhub.io/api/news?id=728b6f2f10d052e542a15011fdef72ee2f6ff39e49f7cc4e571f06743480c9ec"
    }
  },
  {
    "ts": null,
    "headline": "Pulmonary Arterial Hypertension Market Research Report 2025, Competitive Analysis of Gilead Sciences, Viatris, Sandoz, J&J, Sun Pharma, Lupin Pharma, GlaxoSmithKline, Bayer, United Therapeutics",
    "summary": "Market opportunities in the Pulmonary Arterial Hypertension (PAH) sector include increased demand for innovative therapies due to rising PAH prevalence and greater awareness, alongside enhanced diagnostic capabilities. The shift towards personalized medicine and digital health tools also offers avenues for optimizing treatment efficacy and patient management. Pulmonary Arterial Hypertension Market Pulmonary Arterial Hypertension Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The \"Pulmonary Art",
    "url": "https://finnhub.io/api/news?id=9dbbf4dc8b86002bad3ef89f462262a56e4a5db3865beef210259e5f6575822a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762872120,
      "headline": "Pulmonary Arterial Hypertension Market Research Report 2025, Competitive Analysis of Gilead Sciences, Viatris, Sandoz, J&J, Sun Pharma, Lupin Pharma, GlaxoSmithKline, Bayer, United Therapeutics",
      "id": 137448721,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Market opportunities in the Pulmonary Arterial Hypertension (PAH) sector include increased demand for innovative therapies due to rising PAH prevalence and greater awareness, alongside enhanced diagnostic capabilities. The shift towards personalized medicine and digital health tools also offers avenues for optimizing treatment efficacy and patient management. Pulmonary Arterial Hypertension Market Pulmonary Arterial Hypertension Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The \"Pulmonary Art",
      "url": "https://finnhub.io/api/news?id=9dbbf4dc8b86002bad3ef89f462262a56e4a5db3865beef210259e5f6575822a"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Analysts See Johnson & Johnson (JNJ) as a Buy: Should You Invest?",
    "summary": "The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
    "url": "https://finnhub.io/api/news?id=0b34e0347b002c6de5b6b2be85b0da9d3c675940c5f6ef7050dcf0d8ada06746",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762871403,
      "headline": "Wall Street Analysts See Johnson & Johnson (JNJ) as a Buy: Should You Invest?",
      "id": 137448722,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
      "url": "https://finnhub.io/api/news?id=0b34e0347b002c6de5b6b2be85b0da9d3c675940c5f6ef7050dcf0d8ada06746"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Presents at UBS Global Healthcare Conference 2025 Transcript",
    "summary": "Johnson & Johnson (JNJ) UBS Global Healthcare Conference 2025 November 11, 2025 11:00 AM ESTCompany ParticipantsPeter MenziusoConference Call...",
    "url": "https://finnhub.io/api/news?id=22928edf94adf08e44f17b3ce40ab6828ef4d07a741ed104a3b444d0f26c2a0b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762868496,
      "headline": "Johnson & Johnson (JNJ) Presents at UBS Global Healthcare Conference 2025 Transcript",
      "id": 137449679,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson (JNJ) UBS Global Healthcare Conference 2025 November 11, 2025 11:00 AM ESTCompany ParticipantsPeter MenziusoConference Call...",
      "url": "https://finnhub.io/api/news?id=22928edf94adf08e44f17b3ce40ab6828ef4d07a741ed104a3b444d0f26c2a0b"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript",
    "summary": "Johnson & Johnson (JNJ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 10:30 AM ESTCompany ParticipantsSarah...",
    "url": "https://finnhub.io/api/news?id=43b18a82868ee247b39b664e2cf31c5eb298efc7babce0b42be4e81d12f13de3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762865496,
      "headline": "Johnson & Johnson (JNJ) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript",
      "id": 137448411,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson (JNJ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 10:30 AM ESTCompany ParticipantsSarah...",
      "url": "https://finnhub.io/api/news?id=43b18a82868ee247b39b664e2cf31c5eb298efc7babce0b42be4e81d12f13de3"
    }
  },
  {
    "ts": null,
    "headline": "Globus Medical: Straightening Its Back",
    "summary": "Globus Medical surges on strong Q3 results and successful acquisitions. Read here to know if GMED stock's current valuation offers growth potential.",
    "url": "https://finnhub.io/api/news?id=a9877d4a69ef641e574d80ff31bd0d4386d3e232ffbac23eef633a9372c8461d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762855223,
      "headline": "Globus Medical: Straightening Its Back",
      "id": 137447605,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1860536835/image_1860536835.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Globus Medical surges on strong Q3 results and successful acquisitions. Read here to know if GMED stock's current valuation offers growth potential.",
      "url": "https://finnhub.io/api/news?id=a9877d4a69ef641e574d80ff31bd0d4386d3e232ffbac23eef633a9372c8461d"
    }
  }
]